Top Page
AstraZeneca
(LSE:AZN)
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Earnings Call Summary
AstraZeneca Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 58.74B | 52.94B | 46.58B | 44.25B | 37.11B |
| Gross Profit | 48.11B | 39.70B | 34.45B | 28.04B | 22.60B |
| EBITDA | 19.83B | 14.86B | 13.20B | 8.63B | 4.59B |
| Net Income | 10.22B | 6.89B | 6.06B | 3.28B | 109.85M |
Balance Sheet | |||||
| Total Assets | 114.07B | 104.03B | 101.12B | 96.48B | 105.36B |
| Cash, Cash Equivalents and Short-Term Investments | 5.74B | 5.65B | 5.91B | 6.24B | 6.37B |
| Total Debt | 29.62B | 30.11B | 28.41B | 29.14B | 30.69B |
| Total Liabilities | 65.36B | 63.16B | 61.95B | 59.42B | 66.08B |
| Stockholders Equity | 48.67B | 40.79B | 39.14B | 37.04B | 39.27B |
Cash Flow | |||||
| Free Cash Flow | 8.67B | 7.28B | 6.57B | 7.24B | 3.76B |
| Operating Cash Flow | 14.57B | 11.86B | 10.35B | 9.81B | 5.96B |
| Investing Cash Flow | -6.81B | -7.98B | -4.06B | -2.96B | -11.06B |
| Financing Cash Flow | -7.54B | -4.00B | -6.57B | -6.82B | 3.65B |
AstraZeneca Technical Analysis
AstraZeneca Risk Analysis
AstraZeneca Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £224.87B | 28.13 | 22.34% | 1.53% | 10.20% | 40.57% | |
70 Outperform | £10.91B | 10.55 | 9.30% | 2.35% | 2.51% | 56.56% | |
69 Neutral | £81.66B | 12.93 | 37.19% | 3.29% | 2.73% | 119.38% | |
67 Neutral | £4.75B | 37.08 | 10.53% | 2.11% | 4.18% | 37.65% | |
59 Neutral | £2.65B | 11.21 | 15.83% | 4.16% | 3.73% | 27.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
AstraZeneca Corporate Events
AstraZeneca has entered a strategic collaboration with China’s CSPC Pharmaceuticals to expand its weight management portfolio, securing exclusive rights outside China to CSPC’s once‑monthly injectable obesity and type 2 diabetes therapies, including a Phase I‑ready long‑acting GLP1R/GIPR agonist and three preclinical assets. The agreement, which also grants AstraZeneca access to CSPC’s AI‑driven peptide discovery platform and LiquidGel once‑monthly dosing technology, is structured around an upfront payment of $1.2 billion plus up to $3.5 billion in development and regulatory milestones and additional commercial payments, and is expected to strengthen AstraZeneca’s competitive position in the fast‑growing obesity market by complementing its existing pipeline of next‑generation weight management drugs while potentially improving patient adherence through simplified, sustained‑release regimens.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca will invest $15 billion in China through 2030 to expand its research, development and manufacturing footprint, deepening its presence in advanced modalities such as cell therapy and radioconjugates and reinforcing China’s role as a strategic hub in its global pipeline. The landmark programme, announced during the UK Prime Minister’s visit to China, aims to build end‑to‑end cell therapy capabilities, upgrade and add manufacturing sites, expand its Chinese workforce beyond 20,000, and strengthen China‑UK life sciences collaboration, positioning the company to accelerate innovative drug development and broaden patient access in China while supporting jobs and research ecosystems in both countries.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £163.89 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca will voluntarily withdraw the listing of its American Depositary Shares and certain US dollar-denominated debt securities from Nasdaq as it completes a direct listing of its ordinary shares and all US debt securities on the New York Stock Exchange after market close on 30 January 2026. The move forms part of a shareholder-approved plan to harmonise the company’s share listing structure, creating a unified global platform that allows investors to trade AstraZeneca’s ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the NYSE under the unchanged ticker AZN, and is intended to simplify access for global investors and support the company’s positioning as a globally traded biopharmaceutical leader.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £110.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has appointed Joris Silon as Head of Investor Relations, effective 1 March 2026, succeeding Andy Barnett and based in Cambridge, UK. Silon moves into the role from his position as country president of AstraZeneca US, where he oversaw significant growth in the company’s largest market, bringing more than two decades of global leadership experience across Asia, Europe and the US. The appointment underscores AstraZeneca’s focus on strengthening its engagement with the investment community as it enters a new phase of growth, while Barnett transitions to another senior role within the company, maintaining continuity in its investor relations strategy and leadership.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has confirmed that, as of 31 December 2025, its issued share capital with voting rights consists of 1,550,907,927 ordinary shares, with no shares held in treasury, establishing the total number of voting rights at the same figure. This disclosure, made under UK Financial Conduct Authority transparency rules, provides shareholders and market participants with the reference denominator needed to assess and report any holdings or changes in holdings, supporting regulatory compliance and ensuring clarity around AstraZeneca’s equity base and governance structure.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca disclosed that non-executive director Nazneen Rahman sold 297 ordinary shares in the company at a price of £134.96 per share on 18 December 2025, in a transaction carried out on the London market and reported under UK market abuse regulations. The relatively small director share sale is a routine governance disclosure rather than a signal of a strategic shift, but it nonetheless provides transparency for investors monitoring insider dealings in one of the UK’s largest biopharmaceutical groups.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca and Daiichi Sankyo’s HER2-directed antibody drug conjugate Enhertu has received US FDA Breakthrough Therapy Designation as a post‑neoadjuvant treatment for adults with HER2‑positive early breast cancer who have residual invasive disease and a high risk of recurrence after initial therapy. The designation, based on positive Phase III DESTINY‑Breast05 data showing superior outcomes versus current standard T‑DM1, marks the drug’s tenth such status and underscores its potential to reshape care in early‑stage, high‑risk HER2‑positive disease, complementing an expanding label that already spans multiple metastatic breast, lung, gastric and solid tumour indications and reinforcing AstraZeneca’s and Daiichi Sankyo’s competitive leadership in the fast‑growing ADC oncology market.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca reported that its Phase III LATIFY trial testing the ATR inhibitor ceralasertib in combination with its immunotherapy Imfinzi in patients with previously treated, locally advanced or metastatic non-small cell lung cancer failed to meet its primary endpoint of improving overall survival compared with standard chemotherapy agent docetaxel. The company said the combination was generally well tolerated with no new safety signals and confirmed that full data will be shared at an upcoming medical meeting, underscoring both the challenges of extending immunotherapy benefits in heavily pre-treated lung cancer patients and AstraZeneca’s continued strategic emphasis on novel oncology combinations despite this setback.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has disclosed an internal share transfer involving Non-Executive Director and PDMR Philip Broadley, who gifted 5,735 ordinary shares in the company to his spouse, Gillian Broadley, for no consideration on 17 December 2025. The off-market transaction, notified in line with UK Market Abuse Regulation requirements, represents a reallocation of shares within a closely associated person group rather than a change in overall insider ownership, and is primarily relevant for transparency and compliance purposes rather than signalling any shift in the company’s strategic or financial outlook.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Saphnelo has been approved by the European Union for subcutaneous self-administration as a pre-filled pen for treating systemic lupus erythematosus (SLE), providing a more convenient option for patients. This approval is based on positive results from the Phase III TULIP-SC trial, which demonstrated significant reductions in disease activity. The new administration method is expected to expand patient access and choice, enhancing treatment flexibility and potentially improving outcomes for those affected by this debilitating autoimmune disease.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved in the US for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. This approval, based on the DESTINY-Breast09 Phase III trial results, marks the first new treatment in over a decade to show a significant improvement in progression-free survival over the current standard regimen. The combination therapy reduced the risk of disease progression or death by 44% and extended median progression-free survival to over three years. This development is expected to set a new standard of care and has significant implications for improving long-term outcomes for patients with HER2-positive metastatic breast cancer.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca PLC announced that as of November 30, 2025, its issued share capital with voting rights consists of 1,550,725,869 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s rules, which could impact shareholder engagement and transparency in the company’s governance.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as the first perioperative immunotherapy for early-stage gastric and gastroesophageal junction cancers, based on the MATTERHORN Phase III trial results. This approval, which follows a Priority Review by the FDA, marks a significant advancement in the treatment of these cancers, offering a new standard of care with a notable survival benefit. The Imfinzi regimen, combined with FLOT chemotherapy, demonstrated a 29% reduction in disease progression risk and a 22% reduction in death risk compared to chemotherapy alone, establishing a new clinical paradigm and providing renewed hope for patients.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced a $2 billion investment to expand its manufacturing operations in Maryland, which will support 2,600 jobs and boost economic growth. This expansion includes enhancing its biologics manufacturing facility in Frederick and building a new state-of-the-art facility in Gaithersburg, both of which will be operational by 2029. The move is part of AstraZeneca’s broader $50 billion commitment to medicines manufacturing and R&D, aimed at strengthening the US medicine supply chain and accelerating access to transformative therapies.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £18400.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Koselugo (selumetinib) has been approved by the US FDA for treating adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), based on positive results from the KOMET Phase III trial. This approval marks a significant advancement in treatment options for adults with NF1, building on Koselugo’s established use in pediatric patients, and is expected to enhance AstraZeneca’s position in the rare disease market while providing continuity of care for NF1 patients.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £18400.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.